MW 444.3 Da, Purity >98%. Potent FGF/FGFR inhibitor. Inhibits in vitro autophosphorylation of FGFR-1, FGFR-2, FGFR-3, and FGFR-4 with similar inhibition potency for all four FGFRs (IC50 < 6.4 nM). Exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.
Images
Publications
Filter by
- Nature communications 12:36792021A single cell characterisation of human embryogenesis identifies pluripotency transitions and putative anterior hypoblast centre.Applications:Unspecified applicationReactive species:Unspecified reactive speciesMatteo A Molè,Tim H H Coorens,Marta N Shahbazi,Antonia Weberling,Bailey A T Weatherbee,Carlos W Gantner,Carmen Sancho-Serra,Lucy Richardson,Abbie Drinkwater,Najma Syed,Stephanie Engley,Philip Snell,Leila Christie,Kay Elder,Alison Campbell,Simon Fishel,Sam Behjati,Roser Vento-Tormo,Magdalena Zernicka-GoetzPubMed 34140473
Key facts
- CAS number
- 1254473-64-7
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 444.3 Da
- Molecular formula
- C21H19Cl2N5O2
- PubChem identifier
- 46944259
- Nature
- Synthetic
Target data
Alternative names
AS, BFGFR, Basic fibroblast growth factor receptor 1, Beta-interferon, CD309, CD309 antigen, CD331, CEK, EC 2.7.10.1, FGFBR, FGFR1/PLAG1 fusion, FGFR1_HUMAN, FLG, FLK-1, FLK1, mouse, homolog of, FLT-2, Fetal liver kinase 1, Fibroblast interferon, Fms-like gene, Fms-like tyrosine kinase 2, HBGFR, HH2, HLA B protein, HLA class I histocompatibility antigen, B alpha chain, HLA-B histocompatibility type, HRTFDS, IFB, IFF, IFN-beta, IFNB 1, IFNB_HUMAN, Interferon beta, Interferon beta 1 fibroblast, Interferon beta precursor, KAL2, KRD1, Kdr, Kinase insert domain receptor, Kinase insert domain receptor (a type III receptor tyrosine kinase), Ly73, Lymphocyte antigen, MGC96956, MHC Class I HLA heavy chain, MHC HLA-B cell surface glycoprotein, MHC HLA-B transmembrane glycoprotein, MHC class I antigen GN00104, MHC class I antigen HLA-B heavy chain, MHC class I antigen SHCHA, N-SAM, OGD, Protein-tyrosine kinase receptor flk-1, Proto-oncogene c-Fgr, SPDA1, Tyrosine kinase growth factor receptor, VEGFR, VEGFR-2, VGFR2_HUMAN, Vascular endothelial growth factor receptor 2, bFGF-R-1, fibroblast growth factor receptor 1, fms-related tyrosine kinase 2, heparin-binding growth factor receptor, hydroxyaryl-protein kinase, leukocyte antigen class I-B, major histocompatibility complex, class I, B, soluble VEGFR2
Recommended products
MW 444.3 Da, Purity >98%. Potent FGF/FGFR inhibitor. Inhibits in vitro autophosphorylation of FGFR-1, FGFR-2, FGFR-3, and FGFR-4 with similar inhibition potency for all four FGFRs (IC50 < 6.4 nM). Exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.
Key facts
- CAS number
- 1254473-64-7
- Purity
- > 98%
- Form
- Solid
- Molecular weight
- 444.3 Da
- Molecular formula
- C21H19Cl2N5O2
- PubChem identifier
- 46944259
- Nature
- Synthetic
- Solubility
DMSO (>4 mg/ml).
- Biochemical name
- LY-2874455
- Biological description
Potent FGF/FGFR inhibitor. Inhibits in vitro autophosphorylation of FGFR-1, FGFR-2, FGFR-3, and FGFR-4 with similar inhibition potency for all four FGFRs (IC50 < 6.4 nM). Exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.
- Canonical SMILES
- CC(C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3C=CC4=CN(N=C4)CCO
- Isomeric SMILES
- C[C@H](C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3/C=C/C4=CN(N=C4)CCO
- InChI
- InChI=1S/C21H19Cl2N5O2/c1-13(21-17(22)10-24-11-18(21)23)30-15-3-5-20-16(8-15)19(26-27-20)4-2-14-9-25-28(12-14)6-7-29/h2-5,8-13,29H,6-7H2,1H3,(H,26,27)/b4-2+/t13-/m1/s1
- InChIKey
- GKJCVYLDJWTWQU-CXLRFSCWSA-N
- IUPAC name
- 2-[4-[(E)-2-[5-[(1R)-1-(3,5-dichloropyridin-4-yl)ethoxy]-1H-indazol-3-yl]ethenyl]pyrazol-1-yl]ethanol
Storage
- Shipped at conditions
- Blue Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
- Storage information
- Store in the dark, Store under desiccating conditions
Notes
This product is manufactured by BioVision, an Abcam company and was previously called 9532 LY-2874455. 9532-25 is the same size as the 25 mg size of ab216313.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Interferon beta also called IFN-β is a cytokine produced by fibroblasts and immune cells like macrophages. It has a molecular mass of approximately 20 kDa. You can find it expressed in various tissues including spleen liver and lung. As a type I interferon its main role is to regulate the immune response especially during viral infections.
- Biological function summary
Interferon beta works by inhibiting viral replication within host cells. It does so by triggering a complex signaling cascade via the JAK-STAT pathway. This cascade induces the expression of interferon-stimulated genes (ISGs) which boost the antiviral state of cells. Moreover Interferon beta modulates immune functions and inflammation contributing to its therapeutic roles in immune-related disorders.
- Pathways
Interferon beta activates the JAK-STAT signaling and also impacts MAPK pathways. These pathways regulate not only antiviral responses but also cell proliferation and apoptosis. Interferon beta interacts closely with other proteins in these pathways such as Signal Transducer and Activator of Transcription 1 (STAT1) and STAT2 leading to enhanced antiviral and immunomodulatory effects.
- Associated diseases and disorders
Interferon beta plays a significant role in the management of multiple sclerosis and hepatitis C. In multiple sclerosis it helps modulate the immune system to prevent harmful autoimmunity. Interferon beta's action involves reducing the activity of pro-inflammatory cytokines and improving the balance with anti-inflammatory cytokines. The protein also has a connection with Viral Hepatitis via interactions with viral RNA making it a critical component of antiviral therapy.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Chemical Structure - LY2874455, FGF/FGFR inhibitor (ab216313)
2D chemical structure image of ab216313, LY2874455, FGF/FGFR inhibitor
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com